* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Principlesofdruguseinpregnancy2
Survey
Document related concepts
Specialty drugs in the United States wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Drug design wikipedia , lookup
Orphan drug wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Transcript
Principles of drug use in pregnancy Swansea NHS Trust Scott Pegler Clinical & Information Pharmacist Swansea NHS Trust Company LOGO History Thalidomide: probably the most notorious human teratogen Marketed as a sedative in late 1950’s Associated with up to 12,000 birth defects, primarily phocomelias Other effects included: facial hemangiomata, oesophageal & duodenal atresia, teratology of Fallot, renal agenesis & anomalies of the external ear Thalidomide No malformations if taken before the 34th day after last menstruation & usually no malformations if taken after the 50th day Sensitive time period: day 35 to day 49 Day 35 – 37: absence of ears & deafness Day 39 – 41: absence of arms Day 43 – 44: phocomelia with three fingers Day 46 – 48: thumbs with three joints If taken throughout the sensitive period: severe defects of the ears, arms & legs & internal malformations often leading to early death (40% died before their 1st birthday) Thalidomide Association between thalidomide and human teratogenicity suspected by Lenz (Germany) in November 1961 & endorsed by a letter by McBride to the Lancet in November 1961 Withdrawn in Germany at the end of Nov 1961 end of malformation ‘epidemic’ seen in July 1962 (as predicted) Thalidomide continued to be sold for several months in some countries e.g. Belgium, Brazil, Canada, Italy & Japan Finally withdrawn in Japan in Sept 1962 peak in epidemic occurred in Japan at a time when epidemic had ended in Germany Thalidomide 20% of pregnancies exposed during this period resulted in anomalies Administration to female rabbits did not show any adverse effects on fertility There was an increase in early pregnancy loss (equivalent to miscarriage) There were no thalidomide-associated malformations in surviving foetuses Overview All drugs should be avoided in pregnancy unless they are ‘essential’ In practice, it may not be easy to know what treatment is really necessary or whether a particular medicine is an appropriate choice Requires a balanced approach: Being over-cautious may deny a beneficial therapy Lack of due caution might harm babies as a consequence of drug exposure Benefits of treatment need to be weighed against the risks of giving no medication Note: while the benefits of Tx may be clear, the risks may be largely unknown or unquantifiable For minor conditions, the risks almost always outweigh the (often trivial) benefits The problem 80% of women use prescribed or OTC drugs during pregnancy 3 – 8 different drugs (partly prescribed and partly self-medication) The risks of drug use in pregnancy has lagged far behind advances in other areas of pharmacotherapy Main reasons: epidemiological difficulties in establishing causality and ethical barriers to prospective RCTs Teratogenicity and drugs In the UK, the spontaneous malformation rate at birth is 2-3% i.e. approximately 1 in 40 babies will be born with a malformation The incidence of malformations increases to approximately 5% by 4-5 years of age Drugs are thought to cause less than 1% of malformations Therapeutic drugs do not appear to be a significant cause of birth defects However, most birth defects have no known cause and exposure to drugs may play a part in some of these Causes of developmental disorders • Unknown:- Spontaneous development disorders; multigenetic conditions; combination and interactions of exogenic and endogenic factors (65%) • Genetic diseases:- (20%) • Chromosomal disorders:- (5%) • Anatomical factors:- Uterus anomalies; twin pregnancy; oligohydramy (2%) • Maternal conditions:- Diabetes mellitus; hypothyroidism; phenylketonuria; cytomegaly; listeriosis; lues; rubella; toxoplasmosis; Varicella (4%) • Chemical and physical agents:- Medicinal products; drugs of abuse (especially alcohol); ionizing radiation; hyperthermia; environmental chemicals (4%) Evaluating drug safety in pregnancy Most birth defects are rare & so an increased risk posed by a teratogen may not be easily identified Most suspected teratogens cause only a relatively small increase in baseline risk of malformations Epileptic women treated with anticonvulsant drugs have a 2-3 fold increased risk of malformations, i.e. a 10% risk of having an abnormal baby. …or at least a 90% chance of having a normal baby Evaluating drug safety in pregnancy Epidemiological studies of drug exposure in pregnancy require large numbers of exposed infants to prove or disprove the teratogenic potential of a drug – few have the statistical power as they cannot include sufficient patients e.g. 1,600 live births following 1st trimester exposure to aciclovir would need to be monitored to detect a 5fold increase in the risk of a specific defect which occurs as frequently as 1 per 1000 live births, with an 80% power For these reasons, no drug is safe beyond all doubt in early pregnancy Evaluating drug safety in pregnancy Animal studies are required before new drugs are licensed, but it is difficult to extrapolate findings to human pregnancy Drugs which produce defects in animals can be relatively safe in humans e.g. corticosteroids Of over 2,000 drugs, chemicals & environmental agents shown to be teratogenic in animals, less than 50 are proven human teratogens Some teratogenic drugs ACE inhibitors Renal dysfunction and hypotension in the newborn, decreased skull ossification, hypocalvaria and renal tubular dysgenesis Alcohol Fetal alcohol syndrome Aminoglycosides Deafness, vestibular damage Androgens (e.g. danazol) Masculinisation of female fetus Anti-cancer drugs Multiple defects, abortion Anti-thyroid drugs Fetal goitre Carbamazepine Neural tube defects Cocaine Cardiovascular, central nervous system defects Diethylstilboestrol Vaginal carcinoma after in utero exposure Lithium Cardiovascular defects (Ebstein’s anomaly) Phenytoin Fetal hydantoin syndrome Retinoids Craniofacial, cardiac, central nervous system defects Sodium valproate Neural tube defects Thalidomide Limb-shortening defects, renal malformations, congenital heart disease Warfarin Fetal warfarin syndrome Embryo/fetotoxic risk assessment Generally accepted that the predictive value of animal studies for predicting safety in humans is less than adequate With the exception of androgens, several antimitotic drugs, sodium valproate and vitamin A derivatives, all human teratogens were discovered earlier in man than in animals Most were case studies from alert clinicians rather than epidemiological studies Drugs and the fetus Nearly all drugs, except those with a very high molecular weight e.g. insulin and heparin, cross the placenta to the fetus Lipid-soluble un-ionised drugs cross the placenta more rapidly than polar drugs In practice, all drugs should be regarded as having the potential to affect the unborn child The effect of drug exposure will depend upon: Timing of exposure Dosage Concomitant maternal disease Genetic susceptibility Drugs and the fetus However, it should be remembered that: Teratogens do not cause defects in all fetuses exposed at the critical period of gestation A drug that harms a baby in one pregnancy may have no effect in a subsequent pregnancy in the same woman Timing of drug exposure Exposure during the pre-embryonic period (until 14 days post-conception) the ‘all or nothing effect’ Damage to all or most cells death If only a few cells are injured normal development Women with a history of drug use in the month following their last menstrual period can often be reassured Limitations Drug must be completely eliminated before this time (not useful for drugs with long half-life) Dates of conception uncertain Timing of drug exposure Fetus most vulnerable to teratogens from week 3 to week 8 after conception (embryonic phase) when major organ systems formed For some drugs there is a period of greatest risk Exposure to sodium valproate at the time the neural tube closes (between day 17 & 30 post-conception) may result in spina bifida Cleft palate develops at about 36 days postconception & so a drug exposure outside this period is unlikely to be implicated in any a/e Timing of drug exposure During the fetal period (week 9 birth) the fetus is less susceptible to toxic insults, although some organs (cerebellum & urogenital structures) continue to be formed Exposure is more likely to cause growth retardation or interfere with functional development within specific organ systems Danazol can cause virilisation of a female fetus after 8 weeks gestation Warfarin may cause intracranial haemorrhage in the second & third trimesters Timing of drug exposure Drugs taken close to term cause predictable pharmacological effects Beta-blockers can cause neonatal hypoglycaemia SSRIs can cause withdrawal effects after regular in utero exposure Rarely, exposure can have delayed effects Diethylstilboestrol – synthetic oestrogen used for threatened spontaneous abortion Many female fetuses exposed before the 9th week developed vaginal or cervical cancer later in life Dose & polypharmacy In general teratogenicity is dose dependent Neural tube defects & sodium valproate have shown a correlation with: Total daily dose Dose per administration Peak level achieved Dose is only a relative risk factor Normal babies have been born to women who have received high doses of valproate & vice versa Dose & polypharmacy Risk of malformations increases with exposure to multiple drugs e.g. anti-epileptics 4% incidence of defects for 1 drug 23% incidence for 4+ drugs Potential for confounding with disease severity can be discounted as epilepsy is not thought to be associated with an increase in malformation rate Avoid polypharmacy whenever possible Genetic factors Increasing evidence (mainly from antiepileptic drugs) that genetic factors are important determinants of teratogenic effects Malformation rates may be correlated with high levels of epoxide metabolites of phenytoin in individuals with low activity of epoxide hydrolase Risk communication Clear distinction must be made: Prospective query – choice of therapy in pregnancy (or planned pregnancy) is Tx really necessary? Retrospective – communicating the (un)safety of drugs when exposure during pregnancy has already occurred Detailed risk assessment Health & well-being of mother (maternal history etc.) Drug(s) taken (when?), dose & duration Reason for query e.g. for reassurance vs. help with interpretation of an abnormal scan etc. Pregnancy resources Summary of Product Characteristics Often very general, outdated or misleading thus preventing clinician making an individualised decision with their patient Commonly written to protect the manufacturer from potential liability “Contraindicated in pregnancy” Is the drug embryo- or fetotoxic or did the clinical trials simply exclude pregnant women? Pregnancy resources Individual risk vs. population risk Consider a drug with a relative risk of causing a malformation of 1.2 The risk for an individual is very small To a drug company, the same risk implies an extra 400 malformed children per 100,000 exposed pregnancies (with a background rate of 2%) Pregnancy resources BNF Appendix provides brief information on drugs which may have harmful effects, together with trimester of risk Drugs not listed cannot be assumed to be safe! UK Medicines Information Centres Access numerous independent resources, specialist textbooks & databases e.g. ReproTox UKMi Centres also have links with NTIS (National Teratology Information Service) which in turn has links with NPIS (National Poisons Information Service) & ENTIS (European Network of Teratology Information Services) Principles of prescribing in pregnancy Consider non-drug treatments Avoid all drugs in 1st trimester if possible Avoid drugs known to have harmful effects Avoid new drugs where possible More experience with ‘older drugs’ – greater evidence of safety, but can’t assume they are necessarily safe Avoid polypharmacy Use the lowest effective dose for the shortest duration possible & review regularly Consider the need for dosing changes & TDM due to the effect of pregnancy on drug handling Changes in serum albumin & total body water Thank you Any questions? Company LOGO